Mason Street Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Mason Street Advisors’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-13,219	Closed	-$148K	–	1531
2017 Q3	$148K	Buy	13,219 +462	+4%	+$5.1K	﹤0.01%	1387
2017 Q2	$140K	Buy	12,757 +720	+6%	+$7.2K	﹤0.01%	1385
2017 Q1	$118K	Buy	12,037 +881	+8%	+$8.8K	﹤0.01%	1407
2016 Q4	$120K	Buy	11,156 +875	+9%	+$8.75K	﹤0.01%	1388
2016 Q3	$105K	Buy	10,281 +524	+5%	+$5.71K	﹤0.01%	1383
2016 Q2	$127K	Buy	+9,757	New	+$128K	﹤0.01%	1314

Mason Street Advisors's SCLN Position: Q4 2017 in Review

Mason Street Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 13,219 shares — an estimated $148K sold.

Mason Street Advisors first reported a position in SCLN in Q2 2016 and held it in 6 quarters. The position peaked at $148K in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

Mason Street Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
Mason Street Advisors sold 13,219 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $148K.
Mason Street Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q2 2016 and held it in 6 quarters.
Mason Street Advisors's Sciclone Pharmaceuticals Inc position peaked at $148K in Q3 2017.
0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Mason Street Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.